From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis
Frontiers in Oncology · 10.07.2025 · 15
DOI: 10.3389/fonc.2025.1630726 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 10.07.2025. Verfasst von Ze-Qiang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The gut-bladder axis (GBA), a bidirectional network connecting gastrointestinal and urinary systems, has recently emerged as a pivotal focus in bladder cancer research. Beyond conventional risk factors, gut dysbiosis, aberrant microbial metabolites, and neuro-immune pathway disruptions have been implicated in tumorigenesis and progression. Short-chain fatty acids (SCFAs), microbial-derived metabolites, are shown to indirectly modulate tumor behavior through immune microenvironment regulation and inflammatory response attenuation. Cross-organ crosstalk is further mediated by neural pathways (e.g., vagal signaling) and shared receptors, including the Farnesoid X Receptor (FXR) and Toll-like Receptor 4 (TLR4). Novel therapies leveraging microbial ecology principles demonstrate potential, including immune checkpoint inhibitors combined with microbiota modulation (e.g., Parabacteroides distasonis -enhanced PD-1 efficacy), probiotics to reverse chemoresistance, and microbiota reprogramming for SCFA-targeted strategies. However, molecular mechanisms underlying GBA-host interactions remain poorly characterized. Clinical translation is hindered by limited cohort sizes and interindividual heterogeneity. Current studies, while revealing partial pathways, face methodological inconsistencies, particularly in urinary microbiome profiling, and a lack of longitudinal human data. Future breakthroughs will require multi-omics integration, organoid-based models, and interdisciplinary collaboration to address these gaps.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
- The First School of Clinical Medicine, Gannan Medical University, Ganzhou, Jiangxi, China.
- Department of Urology, Cancer Center, National Regional Medical Center, Guangdong Provincial People's Hospital Ganzhou Hospital, Ganzhou, Jiangxi, China.
- Department of Gastroenterology, Guangdong Provincial Geriatrics Institute, National Key Clinical Specialty, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Gua…
- Department of Gastroenterology, Geriatric Center, National Regional Medical Center, Guangdong Provincial People's Hospital Ganzhou Hospital, Ganzhou, Jiangxi, China.
- Department of Urology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
Zitieren
APA
Liu, Z. Q., Yang, X. Y., Chen, J. H., Ge, S. C., Dai, S. X., Zhu, S. H., & Xian, Z. Y. (2025). From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1630726
Vancouver
Liu ZQ, Yang XY, Chen JH, Ge SC, Dai SX, Zhu SH, et al. From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1630726
BibTeX
@article{Liu2025,
author = {Liu, Ze-Qiang and Yang, Xiao-Ying and Chen, Jia-Hong and Ge, Si-Cheng and Dai, Shi-Xue and Zhu, Sheng-Huang and Xian, Zhi-Yong},
title = {From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis},
journal = {Frontiers in Oncology},
year = {2025},
volume = {15},
doi = {10.3389/fonc.2025.1630726}
}
EUVIMED